The birth of the congressional clinic
This paper investigates the impact of mortality in the districts/states represented in key congressional groups (i.e. committees, subcommittees, and parties) on the public investment in medical research in the US. I focus on National Institutes of Health (NIH) R01 grants awarded between 1985-2002. Exploiting the recomposition of any group after congressional elections, I estimate that the composition of the House Subcommittee on Labor, Health and Human Services, Education and Related Agencies (HouS), impacts the NIH budget: a 1% increase of life-years lost because of a disease in the districts represented in HouS increases the funds for clinical research on that disease by 1.2-3.2%. I also find that this impact results from the larger bargaining power of HouS or the House majority, or both groups, in the budget process. No group significantly impacts the allocation of funds for basic research, or the allocation of funds across states.
|Date of creation:||Oct 2010|
|Date of revision:|
|Note:||View the original document on HAL open archive server: http://halshs.archives-ouvertes.fr/halshs-00564921|
|Contact details of provider:|| Web page: http://hal.archives-ouvertes.fr/|
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Brian Jacob & Lars Lefgren, 2007.
"The Impact of Research Grant Funding on Scientific Productivity,"
NBER Working Papers
13519, National Bureau of Economic Research, Inc.
- Jacob, Brian A. & Lefgren, Lars, 2011. "The impact of research grant funding on scientific productivity," Journal of Public Economics, Elsevier, vol. 95(9-10), pages 1168-1177, October.
- Erik Snowberg & Justin Wolfers & Eric Zitzewitz, 2006.
"Party Influence in Congress and the Economy,"
NBER Working Papers
12751, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
Levine's Working Paper Archive
228400000000000002, David K. Levine.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, MIT Press, vol. 119(3), pages 1049-1090, August.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Jay Bhattacharya & Mikko Packalen, 2008. "Is Medicine an Ivory Tower? Induced Innovation, Technological Opportunity, and For-Profit vs. Non-Profit Innovation," NBER Working Papers 13862, National Bureau of Economic Research, Inc.
- Rodrigo Cerda, 2003. "Drugs, Market Size and Population," Documentos de Trabajo 238, Instituto de Economia. Pontificia Universidad Católica de Chile..
- Frank R. Lichtenberg & Joel Waldfogel, 2003. "Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act," NBER Working Papers 9750, National Bureau of Economic Research, Inc.
- Brian Knight, 2005. "Estimating the Value of Proposal Power," American Economic Review, American Economic Association, vol. 95(5), pages 1639-1652, December.
When requesting a correction, please mention this item's handle: RePEc:hal:psewpa:halshs-00564921. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (CCSD)
If references are entirely missing, you can add them using this form.